Health and Healthcare

Criminal Charges in Drug Insider Trading Scheme

Thinkstock
The U.S. Securities and Exchange Commission (SEC) today filed criminal charges against a former SAC Capital Advisors hedge-fund manager related to an insider trading scheme that generated profits and avoided losses of $276 million related to a failed drug trial. The manager purchased and later sold shares in Elan Corp. (NYSE: ELN) and Pfizer Inc. (NYSE: PFE) after receiving information from a consultant ahead of public announcements first touting, then providing negative information related to an Alzheimer drug treatment.

The manager, Mathew Martoma, has been charged with conspiracy to commit securities fraud and two counts of securities fraud, and faces up to 60 years in prison if convicted.

The SEC is also suing investors in CR Intrinsic, the subsidiary of SAC Capital Advisors that Martoma worked for, and a University of Michigan professor who provided Martoma with the insider information. The professor has a non-prosecution deal with the U.S. Attorney’s office and has been cooperating with the government during the investigation.

Paul Ausick

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.